Boehringer Ingelheim
Family-owned German pharma and the largest private GLP-1 challenger, anchored by survodutide for obesity and MASH
Market Metrics
Net Sales (2024)
€26.8B
+6% (currency-adjusted)
Human Pharma Sales (2024)
€21.9B
Animal Health Sales (2024)
€4.7B
R&D Investment (2024)
€6.2B
23.2% of net sales
Employees
~54,500
Ownership
100% family-owned
Lead GLP-1 Asset
Survodutide (Ph3)
Up to 16.6% weight loss (SYNCHRONIZE-1)
Funding History
Total raised: Privately held (not publicly traded)
| Round | Date | Amount | Valuation | Key Investors |
|---|
Product Specifications
| Asset | Mechanism | Stage | Indications | Notes |
|---|---|---|---|---|
| Survodutide (BI 456906) | GLP-1 / glucagon dual agonist | Phase 3 | Obesity, MASH | Lead metabolic asset, licensed from and co-developed with Zealand Pharma. SYNCHRONIZE-1 reported up to 16.6% weight loss at 76 weeks (Apr 2026). LIVERAGE (MASH) program ongoing |
| Jardiance (empagliflozin) | SGLT2 inhibitor | Marketed | Type 2 diabetes, heart failure, CKD | Cardio-renal-metabolic franchise, marketed in alliance with Eli Lilly |
| Ofev (nintedanib) | Tyrosine kinase inhibitor | Marketed | Idiopathic pulmonary fibrosis, ILD | Leading anti-fibrotic franchise |
Partnerships & Investors
Survodutide originated from Zealand Pharma; Boehringer leads global development and commercialization, with milestone and royalty payments to Zealand
Diabetes alliance (since 2011) underpinning the Jardiance franchise
Key Milestones
Company Founded
Albert Boehringer establishes the business in Ingelheim am Rhein, Germany
Diabetes Alliance with Eli Lilly
Forms a global diabetes alliance with Eli Lilly to jointly develop and commercialize a portfolio of diabetes compounds; Jardiance is the significant product family in the collaboration
SYNCHRONIZE Phase 3 Obesity Program Starts
Starts the survodutide SYNCHRONIZE Phase 3 program in people with overweight or obesity: SYNCHRONIZE-CVOT on 20 Nov 2023, SYNCHRONIZE-1 on 25 Nov 2023 and SYNCHRONIZE-2 on 27 Nov 2023
Survodutide Breakthrough Therapy (MASH)
Survodutide (GLP-1/glucagon dual agonist) receives FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis, announced in October 2024 together with the start of the LIVERAGE Phase 3 trials
SYNCHRONIZE-1 Obesity Results
In people with overweight or obesity without type 2 diabetes, survodutide delivers up to 16.6% weight loss at 76 weeks versus 3.2% on placebo (efficacy estimand)
KPI data tables
Boehringer Ingelheim operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Human Pharma R&D (other therapy areas) | Obesity + cardiometabolic (survodutide, est.) | Animal Health R&D |
|---|---|---|---|
| 2024 | 5,350 | 350 | 500 |
| 2023 | 4,950 | 250 | 600 |
| 2022 | 4,400 | 180 | 420 |
| 2021 | 3,500 | 130 | 450 |
| 2020 | 3,150 | 90 | 460 |
Source: Boehringer Ingelheim annual reports (boehringer-ingelheim.com; published annually for the prior calendar year); Human Pharma + Animal Health R&D split disclosed in the financial review. Reported group/Human-Pharma R&D: 2024 ~EUR 6.2B group / ~EUR 5.7B Human Pharma; 2023 ~EUR 5.8B / ~EUR 5.2B; 2022 ~EUR 5.0B group. The Human-Pharma + Animal-Health totals match reported figures; the obesity/cardiometabolic sub-allocation is estimate-driven because BI does not disclose therapy-area-level R&D budgets.
| Period | Cumulative BI payments to Zealand (EUR millions, estimated) |
|---|---|
| 2024 | 150 |
| 2023 | 140 |
| 2022 | 110 |
| 2020 | 95 |
| 2015 | 55 |
| 2011 | 41 |
Source: Zealand Pharma annual + interim reports (counterparty disclosure of payments received from the Boehringer partnership); original 2011 partnership announcement (lead candidate ZP2929); disclosed milestone receipts (~EUR 20M in 2020, ~EUR 30M in 2023). The cumulative curve is estimate-driven and anchored to these disclosed milestones (Zealand aggregates partner revenue rather than itemizing a BI-specific cumulative figure), so intermediate-year values are approximate.
Frequently asked questions
What does Boehringer Ingelheim do?
Largest private GLP-1 player. Survodutide (dual GLP-1/glucagon, Phase 3 with Zealand) with MASH and obesity readouts expected 2026 to 2027. Family-owned German pharma. Boehringer Ingelheim was founded in 1885, is headquartered in Ingelheim am Rhein, Germany and employs ~54,500 (group).
How much funding has Boehringer Ingelheim raised?
Boehringer Ingelheim has raised Privately held (not publicly traded) in total, based on the funding rounds Sterling tracks.
Who are Boehringer Ingelheim's main competitors?
Sterling groups Boehringer Ingelheim in the GLP-1 industry, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
If I'm investing in Boehringer Ingelheim, what similar companies should I consider?
If you are researching Boehringer Ingelheim, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 industry on Sterling.